BIOCRYST PHARMACEUTICALS INC
For the period ended Jun 12, 2025. Filed Apr 24, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 12, 2025 · Filed Apr 24, 2025
Contents
SUMMARY COMPENSATION TABLE
2024 Summary Compensation Table
The following table sets forth the total compensation awarded, paid to, or earned by our Named Executive Officers, as specified by Item 402(a)(3) of Regulation S-K.
| Name and Principal Position · Year · Salary ($) · Stock Awards ($)(1) · Option Awards ($)(2) · Non-Equity Incentive Plan Compensation ($)(3) · All Other Compensation ($)(4) · Total ($) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jon P. Stonehouse President, Chief Executive Officer, Interim Chief Financial Officer, and Director | 2024 | 705,536 | 2,675,919 | 4,002,134 | 899,558 | 34,139 | (5) | 8,317,286 | ||||||
| 2023 | 665,600 | 819,825 | 2,724,624 | 537,472 | 30,257 | 4,777,778 | ||||||||
| 2022 | 640,000 | 1,355,325 | 4,482,254 | 480,000 | 25,415 | 6,982,994 | ||||||||
| Anthony J. Doyle Former Chief Financial Officer and Treasurer | 2024 | 549,429 | 891,973 | 1,334,133 | 494,486 | 17,250 | 3,287,271 | |||||||
| 2023 | 528,297 | 218,620 | 725,803 | 301,129 | 16,500 | 1,790,349 | ||||||||
| 2022 | 507,978 | 361,420 | 1,194,012 | 203,191 | 15,250 | 2,281,851 | ||||||||
| Helen M. Thackray, M.D.Chief R&D Officer | 2024 | 599,423 | 930,771 | 1,392,012 | 629,394 | 17,250 | 3,568,850 | |||||||
| 2023 | 576,368 | 327,930 | 1,089,850 | 383,285 | 16,500 | 2,393,933 | ||||||||
| 2022 | 554,200 | 861,030 | 1,792,902 | 277,100 | 12,700 | 3,497,932 | ||||||||
| Alane P. BarnesChief Legal Officer and Corporate Secretary | 2024 | 525,442 | 891,973 | 1,334,133 | 472,898 | 17,250 | 3,241,696 | |||||||
| 2023 | 495,700 | 411,520 | 725,803 | 282,549 | 16,500 | 1,932,072 | ||||||||
| 2022 | 457,200 | 361,420 | 1,194,012 | 182,880 | 15,250 | 2,210,762 | ||||||||
| Charles K. GayerChief Commercial Officer | 2024 | 544,830 | 930,771 | 1,392,012 | 490,347 | 17,250 | 3,375,210 | |||||||
| 2023 | 495,300 | 218,620 | 725,803 | 282,321 | 16,500 | 1,738,544 | ||||||||
| 2022 | 448,700 | 361,420 | 1,194,012 | 179,480 | 15,250 | 2,198,862 | ||||||||
(1)For 2024, these amounts reflect the aggregate grant date fair value, computed in accordance with FASB ASC Topic 718, of RSUs granted pursuant to the Stock Incentive Plan for the fiscal year ended December 31, 2024, calculated based on the closing price of our Common Stockas reported by Nasdaqon December 19, 2024 (the date of grant) of $7.39.
(2)For 2024, these amounts reflect the aggregate grant date fair value, computed in accordance with FASB ASC Topic 718, of stock option awards granted pursuant to the Stock Incentive Plan for the fiscal year ended December 31, 2024. Assumptions used in the calculation of these amounts are included in Note 12 to the Company’s audited consolidated financial statements for the year ended December 31, 2024, which is included in the Company’s Annual Report on Form 10-K filed with the SEC on February 25, 2025.
(3)Represents payments earned under the AIP. Values shown reflect the full calculated payout of the incentive awards under the AIP.
(4)Except as otherwise noted, the amounts shown reflect the Company contribution for the executive to his or her 401(k) plan.
(5)Consists of Company contributions to the 401(k) plan and life insurance premiums described above in the Compensation Discussion and Analysis under the caption “Other Elements of Compensation—Life and Disability Insurance.” For 2024, such amounts were $17,250 and $16,889, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.